Regressive changes in finasteride-treated human hyperplastic prostates correlate with an upregulation of TGF-β receptor expression

Sáez, Carmen; González-Baena, Antonio C.; Japón, Miguel Á.; Giráldez, Javier; Segura, Dolores; Miranda, Gonzalo; Rodríguez-Vallejo, José M.; González‐Esteban, Jorge; Torrubia, Francisco

doi:10.1002/(sici)1097-0045(19981001)37:2<84::aid-pros4>3.0.co;2-l

Cited by 31 publications

(17 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The loss or reduction of sensitivity to the TGF-β inhibitory effect and the acquired ability to express higher levels of TGF-β are in part explained by the ability of cells to overwhelm the down-regulatory effects of androgens. These phenomena appear to be associated with the transformation of a prostate tumor from benign to malignant (Saez et al, 1998;Lee et al, 1999).…”

Section: Tgf-βsupporting

confidence: 92%

Prostate cancer: the need for biomarkers and new therapeutic targets

Felgueiras

Silva

Fardilha

2014

J. Zhejiang Univ. Sci. B

View full text Add to dashboard Cite

Prostate cancer (PCa) incidence and mortality have decreased in recent years. Nonetheless, it remains one of the most prevalent cancers in men, being a disquieting cause of men's death worldwide. Changes in many cell signaling pathways have a predominant role in the onset, development, and progression of the disease. These include prominent pathways involved in the growth, apoptosis, and angiogenesis of the normal prostate gland, such as androgen and estrogen signaling, and other growth factor signaling pathways. Understanding the foundations of PCa is leading to the discovery of key molecules that could be used to improve patient management. The ideal scenario would be to have a panel of molecules, preferably detectable in body fluids, that are specific and sensitive biomarkers for PCa. In the early stages, androgen deprivation is the gold standard therapy. However, as the cancer progresses, it eventually becomes independent of androgens, and hormonal therapy fails. For this reason, androgen-independent PCa is still a major therapeutic challenge. By disrupting specific protein interactions or manipulating the expression of some key molecules, it might be possible to regulate tumor growth and metastasis formation, avoiding the systemic side effects of current therapies. Clinical trials are already underway to assess the efficacy of molecules specially designed to target key proteins or protein interactions. In this review, we address that recent progress made towards understanding PCa development and the molecular pathways underlying this pathology. We also discuss relevant molecular markers for the management of PCa and new therapeutic challenges.

show abstract

Section: Tgf-βsupporting

confidence: 92%

Prostate cancer: the need for biomarkers and new therapeutic targets

Felgueiras

Silva

Fardilha

2014

J. Zhejiang Univ. Sci. B

View full text Add to dashboard Cite

show abstract

“…These authors also showed that finasteride down-regulated the expression of the anti-apoptotic proteins- Bcl-xL and Bcl-2, making the prostate cells more susceptible to apoptosis. Other studies on BPH patients treated with finasteride further affirmed the pro-apoptotic effect of finasteride on the epithelial cells (Saez et al, 1998), and increased expression of the pro-apoptotic proteins (Caspases-3, -6, and -9) during finasteride treatment of BPH (Aline et al, 2005). Recent studies also showed increased expression of inhibitors of apoptosis proteins in human prostates with BPH (Rodriguez-Berriguete et al, 2010; Minutoli et al, 2014).…”

Section: Etiology Of Bphmentioning

confidence: 83%

Management of Benign Prostatic Hyperplasia: Could Dietary Polyphenols Be an Alternative to Existing Therapies?

Eleazu¹,

Eleazu

Kalu

2017

Front. Pharmacol.

View full text Add to dashboard Cite

The incidence of benign prostatic hyperplasia (BPH) is gradually on the increase. While conventional drugs such as the α1-adrenergic receptor antagonists and 5α-reductase inhibitors have been found to be useful in the treatment of BPH, the adverse side effects associated with their usage, have led to increased search for alternative means of managing this disease. Furthermore, although surgery has also been suggested to be a sure method, the cost and risks associated with it excludes it as a routine treatment. Dietary polyphenols have gained public interest in recent times due to their roles in the prevention of various diseases that implicate free radicals/reactive oxygen species. However, their roles in the management of BPH have not been explored. Hence, this review on their prospects in the management of BPH and their mechanisms of action. Literature search was carried out in several electronic data bases such as PubMed, Google Scholar, Medline, Agora, and Hinari from1970 to 2017 to identify the current status of knowledge on this concept. The findings from these data bases suggest that while dietary polyphenols may not replace the need for the existing therapies in the management of BPH, they hold promise in BPH management which could be explored by researchers working in this field.

show abstract

“…These include transforming growth factor-b [13], epidermal growth factor [14] and ®broblast growth factor [15±17]. All of these have been shown to play a role in BPH and may increase the vascularity in some cases.…”

Section: Discussionmentioning

confidence: 99%

“…Recently, ®nasteride has been suggested as an option in the treatment of this problem, with promising results [18,19]. The treatment of BPH with ®nasteride has been shown to produce marked changes in the levels of these growth factors, the postulated mechanism including down-regulation of both the growth factor receptors and the hormones themselves [13,14]. Variation in the levels of bcl-2, as well as the rest of the bcl family of gene protein products, has also led to speculation about the role of varying apoptotic rates on the effects of ®nasteride [20].…”

Section: Discussionmentioning

confidence: 99%

Microvessel density in prostatic hyperplasia

Foley

Bailey

2000

BJU International

View full text Add to dashboard Cite

Objectives To examine the prostates from patients with haematuria associated with benign prostatic hyperplasia (BPH) to determine their microvascular anatomy and thus assess histopathological differences in patients with significant haematuria. Patients and methods Prospectively, 11 patients with BPH and haematuria (mean age 70 years) and 19 control patients with BPH alone (mean age 72 years) were identified. Neither group had received hormone manipulation or had been catheterized. The sub‐urothelial compartment of the prostatic urethra in subsequent specimens from transurethral resection was examined using factor VIII/CD‐34 immuno‐histochemistry. The microvessel density (MVD) was calculated by counting vascular cross‐sectional profiles within a 0.81‐mm2 grid. The pathologist studying the specimens was unaware of the patients’ symptoms. Results The median (range) MVD in the haematuria group was 64 (28–137) and in the controls was 27 (14–39) (P < 0.001). Conclusion The MVD was significantly greater in the patients with haematuria, suggesting that suburo‐thelial microvessel proliferation may play an important role in mediating haematuria associated with BPH. This is the first time that a difference has been shown at the cellular level in patients with haematuria and could form an important foundation for subsequent research.

show abstract

Regressive changes in finasteride-treated human hyperplastic prostates correlate with an upregulation of TGF-β receptor expression

Cited by 31 publications

References 32 publications

Prostate cancer: the need for biomarkers and new therapeutic targets

Prostate cancer: the need for biomarkers and new therapeutic targets

Management of Benign Prostatic Hyperplasia: Could Dietary Polyphenols Be an Alternative to Existing Therapies?

Microvessel density in prostatic hyperplasia

Contact Info

Product

Resources

About